Try GOLD - Free

Exciting time for digital health players

BioSpectrum Asia

|

March 2020

Digital Health has gained much importance, development and investment in the last decade. The year 2019, continued the strong upward trend in health innovation funding. With $13.7 billion in total funding across 727 deals, and was the second most-funded year ever, according to Startup Health. Boasting three out of 2019’s top 10 most-funded cities, China cemented its place as a hub for health innovation, and is positioned for continued growth. The last decade saw the emergence of telemedicine, Big Data, disruption in consumer wellness and healthcare, etc. As the digital health industry matures, there will be new challenges pertaining to data privacy, regulations, digital medicines, etc. Let’s look at the possibilities for digital health in the coming decade.

- Ayesha Siddiqui

Exciting time for digital health players

The global digital health market was valued at $ 144.2 billion in 2018 and is expected to reach a value of $393.3 billion by 2024, registering a CAGR of around 18 per cent during 2019-2024, according to the IMARC Group. The digital health market is slowly maturing from a sector dominated by early-stage start-ups to more established companies with validated products. 2019 was marked with the IPOs of several digital companies, some were acquired by Big Tech, and others partnered with Pharma firms from automating clinical trials to drug discovery. Analysis from Rock Health indicates that investments in digital healthcare in 2019 are keeping pace with investments that were made in 2018. While the total number of deals seems likely to stay consistent with 2018, the average size of the deals has increased.

Privacy is paramount

In the recent times, there has been increasing number of hacking-related to healthcare whether it’s WannaCry in 2017 which affected hospitals throughout the world or SingHealth’s (Singapore’s largest group of healthcare institutions) database containing patient personal particulars and outpatient dispensed medicines had been the target of a major cyber-attack in July 2018. These instances have put light on the privacy challenges these smart technologies bring. The privacy concern also cast a dark show over the growth of digital health industry.

Moving forward, digital healthcare companies will have to establish increasingly tight security, stringent privacy policies, and provide more transparency around data use.

Big Tech is big

MORE STORIES FROM BioSpectrum Asia

BioSpectrum Asia

BioSpectrum Asia

Waters launches charge detection mass spectrometry technology

US-based Waters Corporation has unveiled the Waters Xevo Charge Detection Mass Spectrometer (CDMS), delivering unmatched measurement and characterisation for the broadest range of mega-mass biomolecules central to next-generation therapeutics and structural biology.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

Chulalongkorn University launches Thailand's first master's programme in Nurse Anesthesia

The Faculty of Nursing, Chulalongkorn University, has officially launched the \"Master of Nursing Science Programme in Nurse Anesthesia\" - the first of its kind in Thailand.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

WHO strengthens coordination for NTD programmes and supply chain delivery

The World Health Organization (WHO), together with health ministries, pharmaceutical donours, implementing partners and technical support platforms, is strengthening coordination for neglected tropical disease (NTD) programmes and supply chain delivery, through three major back-to-back meetings in Geneva.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

All-in-one coronavirus vaccines to save millions in future pandemics

A new study reveals that vaccines designed to protect against a wide range of coronaviruses could dramatically reduce deaths and economic disruption and limit the need for lockdowns in the event of another global coronavirus pandemic.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

NTU in Singapore introduces Master of Science course in Chinese Medicine

From 2026, Nanyang Technological University (NTU) in Singapore will start offering a Master of Science in Chinese Medicine to develop highly skilled postgraduates with advanced expertise in both the theoretical foundations and practical applications of Chinese medicine.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

ProSpecBio launches Activin-A recombinant protein for brain injury research

Israel-based ProSpecBio, an evolving biotech company dedicated to providing highly purified proteins to the global research community, has announced the launch of its latest product: CHO cell-derived recombinant Activin-A, now available for immediate delivery worldwide.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

PAHO publishes guide for designing AI instructions in public health

The Pan American Health Organization (PAHO) has launched a new guide providing practical advice on how to create Artificial Intelligence (AI) prompts that generate reliable, relevant, and culturally appropriate content across diverse contexts.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

Prerna launches India's first MicroRNA based blood test for breast cancer screening

Precision RNA Biotech (Prerna), a healthcare startup from Hyderabad, India has announced the launch of Cantel, India's first microRNA-based blood test for breast cancer screening.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

Poly Medicure announces acquisition of Citieffe Group for Rs 324 Cr

India-based medtech firm Poly Medicure has announced signing of a definitive agreement to acquire 100 per cent stake in Medistream SA (Group) consisting of Citieffe SRL and its step-down subsidiaries in USA & Mexico, at an Enterprise Value of Rs 324 crore (EUR 31 million).

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

Sumitomo, Novo Nordisk to co-promote obesity drug Wegovy in Japan

Sumitomo Pharma and Novo Nordisk Pharma have entered into a co-promotion agreement in Japan for Wegovy Subcutaneous Injection, a once-weekly subcutaneous injection formulation of GLP-1 receptor agonist indicated for the treatment of obesity disease.

time to read

1 min

BioSpectrum Asia Nov 2025

Translate

Share

-
+

Change font size